Lundbeck, Pharmaceuticals
Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal
Lundbeck A/S agreed to acquire Longboard Pharmaceuticals Inc in a $2.6 billion deal that boosts its drug pipeline for serious brain diseases.The Danish pharmaceutical company is offering shareholders $60 per share in cash for US-based Longboard,
Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management
Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on LBPH stock here.
Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company
H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.
Lundbeck picks up Longboard Pharmaceuticals for $2.6B
Lundbeck’s acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker stated.
Lundbeck drops in on epilepsy drug with $2.6bn Longboard bid
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.
Lundbeck to buy neurology-focused Longboard Pharmaceuticals in $2.6 billion deal
The Danish pharma company Lundbeck said Monday it would buy Longboard Pharmaceuticals in a deal worth $2.6 billion
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
Longboard Pharmaceuticals LBPH announced that it is set to be acquired by Lundbeck A/S for $60 per share in cash, which brings the total deal value to $2.6 billion equity value and $2.5 billion (approximately DKK 17 billion) net of cash,
M&A News: Lundbeck to Acquire Longboard (NASDAQ:LBPH) for $2.6B
Longboard Pharmaceuticals ($LBPH) soared in trading on Monday after announcing that Dutch pharmaceutical company Lundbeck will acquire the company
Danish pharma giant buys San Diego company’s epilepsy drug for $2.6B
Lundbeck, a global drugmaker based in Denmark, has agreed to buy La Jolla-based Longboard Pharmaceuticals for $2.6 billion to ...
FierceBiotech4d
Lundbeck signs $2.5B check for Longboard, seeing blockbuster potential in epilepsy med
After spying blockbuster potential in Longboard Pharmaceuticals’ epilepsy med, brain disease-focused pharma Lundbeck is ...
Denmark's Lundbeck Bets on Epilepsy Drug With $2.6 Billion Longboard Deal
(Reuters) -H Lundbeck A/S has agreed to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion, marking the biggest deal ...
MedCity News5d
Lundbeck’s Neuro-Rare Pipeline Lands Cornerstone Drug via $2.6B Longboard Pharma Acquisition
Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company whose lead asset is in late-stage clinical ...
Yahoo Finance3d
Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn
Lundbeck has signed an agreement to acquire Longboard Pharmaceuticals for $2.6bn equity value in a move set to enhance its capabilities within neuro-rare conditions. Lundbeck has initiated a ...
Crain's Chicago Business4d
Lundbeck to buy California pharma in $2.6 billion deal
The Danish pharmaceutical company, with its US headquarters in Deerfield, is boosting its drug pipeline for serious brain ...
El gigante farmacéutico danés compra el fármaco contra la epilepsia de una empresa de San Diego
Lundbeck, una farmacéutica global con sede en Dinamarca, ha acordado comprar Longboard Pharmaceuticals, con sede en La Jolla, ...